Brief: Innovent Biologics Says First Half 2026 Product Revenue Exceeds RMB8.2 Billion
05/08/2026 02:16
BRIEF-Innovent Biologics Says First Half 2026 Product Revenue Exceeds RMB8.2 Billion Aug 5 (Reuters) - Innovent Biologics Inc 1801.HK:
FIRST HALF 2026 PRODUCT REVENUE EXCEEDS RMB8.2 BILLION, UP OVER 55% Y/Y
Further company coverage: 1801.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis